Literature DB >> 33359010

P2X7 receptor and the NLRP3 inflammasome: Partners in crime.

Pablo Pelegrin1.   

Abstract

Adenosine triphosphate (ATP) is a molecule that on one hand plays a central role in cellular energetics and which on the other is a ubiquitous signaling molecule when released into the extracellular media. Extracellular ATP accumulates in inflammatory environments where it acts as a damage-associated molecular pattern and activates the purinergic P2X receptor 7 (P2X7) in immune cells. P2X7 receptor activation induces the formation of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing 3 (NLRP3) inflammasome and the activation of the inflammatory caspase-1. Caspase-1 causes an inflammatory type of cell death called pyroptosis through the release of pro-inflammatory cytokines and intracellular content. Consequently, intense research efforts have been devoted to the design of novel anti-inflammatory therapies, focusing in particular on the P2X7 receptor and the NLRP3 pathway and the introduction of new blocking molecules in early phase clinical trials.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory drugs; Cytokines; Inflammation; NLRP3 inflammasome; P2X7 receptor

Year:  2020        PMID: 33359010     DOI: 10.1016/j.bcp.2020.114385

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

Review 1.  Lipid-protein interactions regulating the canonical and the non-canonical NLRP3 inflammasome.

Authors:  Malvina Pizzuto; Pablo Pelegrin; Jean-Marie Ruysschaert
Journal:  Prog Lipid Res       Date:  2022-07-25       Impact factor: 14.673

2.  Effects of Purinergic Receptor Deletion or Pharmacologic Modulation on Pulmonary Inflammation in Mice.

Authors:  Gregory S Whitehead; Tadeusz P Karcz; Dilip K Tosh; Young-Hwan Jung; Zhiwei Wen; Ryan G Campbell; Varun Gopinatth; Zhan-Guo Gao; Kenneth A Jacobson; Donald N Cook
Journal:  ACS Pharmacol Transl Sci       Date:  2022-10-05

Review 3.  Emerging Role of the Inflammasome and Pyroptosis in Hypertension.

Authors:  Carmen De Miguel; Pablo Pelegrín; Alberto Baroja-Mazo; Santiago Cuevas
Journal:  Int J Mol Sci       Date:  2021-01-21       Impact factor: 5.923

4.  Metabolic and behavioral features of acute hyperpurinergia and the maternal immune activation mouse model of autism spectrum disorder.

Authors:  Zarazuela Zolkipli-Cunningham; Jane C Naviaux; Tomohiro Nakayama; Charlotte M Hirsch; Jonathan M Monk; Kefeng Li; Lin Wang; Thuy P Le; Simone Meinardi; Donald R Blake; Robert K Naviaux
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

Review 5.  Inflammasome Activation in Pulmonary Arterial Hypertension.

Authors:  Anna Foley; Benjamin E Steinberg; Neil M Goldenberg
Journal:  Front Med (Lausanne)       Date:  2022-01-13

6.  Evaluation of protein kinase D auto-phosphorylation as biomarker for NLRP3 inflammasome activation.

Authors:  Diane Heiser; Joëlle Rubert; Adeline Unterreiner; Claudine Maurer; Marion Kamke; Ursula Bodendorf; Christopher J Farady; Ben Roediger; Frédéric Bornancin
Journal:  PLoS One       Date:  2021-11-12       Impact factor: 3.240

7.  Oxidative Stress Caused by Ozone Exposure Induces Changes in P2X7 Receptors, Neuroinflammation, and Neurodegeneration in the Rat Hippocampus.

Authors:  Raúl Velázquez-Pérez; Erika Rodríguez-Martínez; Marlen Valdés-Fuentes; Noemí Gelista-Herrera; Nancy Gómez-Crisóstomo; Selva Rivas-Arancibia
Journal:  Oxid Med Cell Longev       Date:  2021-11-08       Impact factor: 6.543

Review 8.  Neuroinflammation, Sleep, and Circadian Rhythms.

Authors:  Mark R Zielinski; Allison J Gibbons
Journal:  Front Cell Infect Microbiol       Date:  2022-03-22       Impact factor: 5.293

Review 9.  NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics.

Authors:  Na Lu; Weijia Cheng; Dongling Liu; Gang Liu; Can Cui; Chaoli Feng; Xianwei Wang
Journal:  Front Cell Dev Biol       Date:  2022-04-13

Review 10.  To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question.

Authors:  Serena Janho Dit Hreich; Jonathan Benzaquen; Paul Hofman; Valérie Vouret-Craviari
Journal:  Purinergic Signal       Date:  2021-08-04       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.